The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2016

Filed:

May. 31, 2012
Applicants:

Christoph Freiberg, Wuppertal, DE;

Christiane Otto, Wuppertal, DE;

Lars Linden, Düsseldorf, DE;

Axel Harrenga, Wuppertal, DE;

Mark Trautwein, Wülfrath, DE;

Simone Greven, Dormagen, DE;

Andreas Wilmen, Köln, DE;

Inventors:

Christoph Freiberg, Wuppertal, DE;

Christiane Otto, Wuppertal, DE;

Lars Linden, Düsseldorf, DE;

Axel Harrenga, Wuppertal, DE;

Mark Trautwein, Wülfrath, DE;

Simone Greven, Dormagen, DE;

Andreas Wilmen, Köln, DE;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2869 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01);
Abstract

The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.


Find Patent Forward Citations

Loading…